Navigation Links
New Positron Emission Tomography (PET) Biomarker NVB-64 Visualizes Malignant Breast Tumors

PARK CITY, Utah, Oct. 29 /PRNewswire/ -- Researchers at Thomas Jefferson University in Philadelphia, PA, supported in part by NuView Life Sciences, have published an article in the Journal of Nuclear Medicine reporting preclinical results of a novel PET biomarker designed to selectively detect malignant breast tumors[1]. "All tumors detected with the new biomarker were malignant and expressed the targeted VPAC1 receptors located on the plasma membrane of the tumor cells." These results have led to initiation of clinical trials, supported by NuView, at Jefferson using this agent in patients with known and suspected breast cancer.

To date, the unsettling report that a patient has a "suspicious mass" on an annual mammogram has automatically dictated a costly and invasive needle biopsy. Soon there may be a choice of care in selecting a diagnostic procedure to determine the benign or malignant nature of the mass. Rather than a protracted waiting period to locate a clinician, find time to schedule a biopsy, endure a painful procedure and wait additional days for lab results to be reported; novel procedures such as a NVB64-PET scan may eventually be available to discriminate between malignant and benign lesions. The results of benign or malignant status of the mass could immediately be available without the anxiety of the delay normally associated with a lab processing and reporting of results from a needle biopsy.[2]

Since 1985, surgical biopsy has been the mainstay of diagnostics for evaluating nonpalpable mammographic abnormalities. In the early 1990's needle biopsy of the breast was introduced and quickly became the preferred method of breast cancer detection. Not until 2004 was the first non-surgical procedure looking towards breast cancer detection using Positron Emission Tomography (PET) with 18fluorodeoxyglucose (FDG) approved for use in patients. FDG-PET has two significant drawbacks: 1) FDG-PET leaves a frustrating 30% of tumors undetected; and 2) FDG cannot reliably distinguish between benign and malignant tumors.

The significant advance of NVB-64 is the recognition of genetic changes at the cellular level, as a genomic biomarker, rather than the overly generalized metabolic markers found with FDG.

Nearly as important as the human implications are the enormous financial ramifications. Lead investigator Mathew Thakur Ph.D. Professor of Radiology and Director of the Laboratories of Radiopharmaceutical Research and Molecular Imaging at Thomas Jefferson University Hospital says, "The use of NVB64-PET scan in the future may minimize the need for unnecessary biopsy of benign tumors." Currently, nearly 6 million such biopsies are performed annually in the United States, at an estimated annual cost of $30 billion. Approximately 80% or 4.8 million biopsies, demonstrate benign pathology.

The biomarkers NuView has in development can, with alteration of the radionuclide attached to the compound, change them from a diagnostic to a targeted therapy, or a pairing of a target specific diagnostic and therapy. NuView Medical Director Peter S. Conti, MD, PhD adds, "Development of targeted diagnostics that can be modified to also carry therapeutic isotopes can lead to unique agents that can broaden the range of therapies available for cancer patients."

Anticipated Benefits of NVB-64:

  • Same day, immediate confirmation of the patient having either benign or malignant breast tumor(s).
  • Choice of care in selecting a screening method to determine the malignant or benign status of a mass found on a mammogram.
  • Significant cost savings to patients and insurers. The cost of the NVB64-PET scan is anticipated at $2,000. This translates to a 60% cost savings over a typical needle biopsy of the breast.

For patients, clinicians and physicians NVB-64 could represent a tremendous step forward in personalizing medical management. Future advances in this genomic biomarker arena hold great promise for both diagnostics and treatment therapies.

    For more information please contact:

    NuView Life Sciences
    Erin Egan
    435-647-9758  Office
    866-577-7774  Toll Free

SOURCE NuView Life Sciences

SOURCE NuView Life Sciences
Copyright©2009 PR Newswire.
All rights reserved

Related medicine technology :

1. FluoroPharma Announces Positive Phase I Safety Results for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
2. FluoroPharma Announces Commencement of Phase I Clinical Trial for BFPET(TM), Myocardial Perfusion Imaging (MPI) Tracer for Positron Emission Tomography (PET)
3. FluoroPharma Announces Positive Phase I Safety Results for CardioPET(TM), Coronary Artery Disease (CAD) Imaging Tracer for Positron Emission Tomography (PET)
4. OPAXIO Produces High Rates of Pathologic Complete Remission in Patients with Advanced Esophageal Cancer; Study Paves Way for Potential Registration Trial as Radiation Sensitizer
5. 18 month Follow-up Data on Phase III Study of Pixantrone in Late Stage Relapsed or Refractory, Aggressive Non-Hodgkins Lymphoma Continues to Demonstrate Significant Improvement in Complete Remission and Progression Free Survival Over Standard Chemotherap
6. Responses After Completion of Therapy Increase Pixantrone Complete Remission (CR)/Unconfirmed Complete Remission (CRu) Rate to 24% and Overall Response Rate (ORR) to 40% Compared to 7% and 14% for Comparator Agents in Phase III EXTEND Trial in 3rd Line Th
7. Pixantrone in Combination with Chemotherapy Regimens Produces Overall Response Rates of 58-74% with Complete Remission Rates of 37-57% in Relapsed/Refractory Aggressive or Indolent NHL
8. Paclitaxel Poliglumex (OPAXIO(TM)) Added to Cisplatin and Radiation Produces 45% Pathologic Complete Remissions in Patients With Esophageal Cancer
9. Pixantrone Produces High Rates of Complete and Partial Remissions Even Among Aggressive NHL Patients With Extensive Prior Doxorubicin Treatment or Prior Rituximab Treatment
10. Compared to Standard Therapies, Pixantrone Decreases Time to Achieve Complete Remission by 47% in Relapsed Aggressive Non-Hodgkins Lymphoma
11. Zevalin Consolidation in Patients With Complete Remission After Induction Therapy Results in Durable Remission of More Than 67 Months
Post Your Comments:
(Date:11/30/2015)... Diagnostics, the U.S.-based manufacturer of point-of-care biometric testing devices ... systems, and PTS Detect™ cotinine systems, has announced the ... the company into the mHealth market. ... The technology is a system that interfaces with mobile ... and uses test strip technology already developed by PTS ...
(Date:11/30/2015)... and ST. LOUIS , Nov. ... (NASDAQ: ESRX ) today announced an early renewal ... which began in 1999, will now extend through at ... --> After evaluating pharmacy benefit manager capabilities during ... Express Scripts continues to offer the best health plan ...
(Date:11/30/2015)... 30, 2015   Nuance Communications, Inc. (NASDAQ: ... Support Company (NDSC) today jointly announced a new ... that utilize the American College of Radiology,s (ACR) Imaging ... to comply with current and emerging value-based payment ... --> By combining clinical decision support, radiology reporting ...
Breaking Medicine Technology:
(Date:11/30/2015)... ... November 30, 2015 , ... A novel class of antimicrobials ... effective in fighting methicillin-resistant Staphylococcus aureus (MRSA), one of the major drug-resistant bacterial ... small molecule analogs that target the functions of SecA, a central part of ...
(Date:11/30/2015)... ... 30, 2015 , ... Using a combination of two blood sugar tests rather ... according to a new study by researchers at the School of Public Health at ... Using Combinations of Blood Glucose Tests ,” published in Frontiers in Public Health, the ...
(Date:11/30/2015)... PA (PRWEB) , ... November 30, 2015 , ... ... to a new study by UPMC and KingMed Diagnostics ... over three years found that consultation with UPMC pathologists resulted in significantly altered ...
(Date:11/30/2015)... ... 30, 2015 , ... The Foundation for Breast and Prostate ... joining forces with the award-winning creator and writer of Downton Abbey Julian Fellowes ... at the Union League of Philadelphia. , The benefit, titled “An Evening ...
(Date:11/30/2015)... , ... November 30, 2015 , ... ... for the last 15 years, announced today that Michigan-based Family Health Center (FHC) ... care for over 45 years, FHC was awarded the largest Affordable Care Act ...
Breaking Medicine News(10 mins):